Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human pluripotent stem cell modeling of alveolar type 2 cell dysfunction caused by ABCA3 mutations
Yuliang L. Sun, Erin E. Hennessey, Hillary Heins, Ping Yang, Carlos Villacorta-Martin, Julian Kwan, Krithi Gopalan, Marianne James, Andrew Emili, F. Sessions Cole, Jennifer A. Wambach, Darrell N. Kotton
Yuliang L. Sun, Erin E. Hennessey, Hillary Heins, Ping Yang, Carlos Villacorta-Martin, Julian Kwan, Krithi Gopalan, Marianne James, Andrew Emili, F. Sessions Cole, Jennifer A. Wambach, Darrell N. Kotton
View: Text | PDF
Research Article Cell biology

Human pluripotent stem cell modeling of alveolar type 2 cell dysfunction caused by ABCA3 mutations

  • Text
  • PDF
Abstract

Mutations in ATP-binding cassette A3 (ABCA3), a phospholipid transporter critical for surfactant homeostasis in pulmonary alveolar type II epithelial cells (AEC2s), are the most common genetic causes of childhood interstitial lung disease (chILD). Treatments for patients with pathological variants of ABCA3 mutations are limited, in part due to a lack of understanding of disease pathogenesis resulting from an inability to access primary AEC2s from affected children. Here, we report the generation of AEC2s from affected patient induced pluripotent stem cells (iPSCs) carrying homozygous versions of multiple ABCA3 mutations. We generated syngeneic CRISPR/Cas9 gene-corrected and uncorrected iPSCs and ABCA3-mutant knockin ABCA3:GFP fusion reporter lines for in vitro disease modeling. We observed an expected decreased capacity for surfactant secretion in ABCA3-mutant iPSC-derived AEC2s (iAEC2s), but we also found an unexpected epithelial-intrinsic aberrant phenotype in mutant iAEC2s, presenting as diminished progenitor potential, increased NFκB signaling, and the production of pro-inflammatory cytokines. The ABCA3:GFP fusion reporter permitted mutant-specific, quantifiable characterization of lamellar body size and ABCA3 protein trafficking, functional features that are perturbed depending on ABCA3 mutation type. Our disease model provides a platform for understanding ABCA3 mutation–mediated mechanisms of alveolar epithelial cell dysfunction that may trigger chILD pathogenesis.

Authors

Yuliang L. Sun, Erin E. Hennessey, Hillary Heins, Ping Yang, Carlos Villacorta-Martin, Julian Kwan, Krithi Gopalan, Marianne James, Andrew Emili, F. Sessions Cole, Jennifer A. Wambach, Darrell N. Kotton

×

Figure 5

Bulk RNA-Seq of ABCA3 mutant iAEC2s reveals upregulation of inflammatory pathways including the NFκB pathway.

Options: View larger image (or click on image) Download as PowerPoint
Bulk RNA-Seq of ABCA3 mutant iAEC2s reveals upregulation of inflammatory...
(A) Schematic for RNA-Seq profiling of sorted, pure populations of day 43–44 SFTPCtdTomato+ syngeneic patient iAEC2s versus their gene corrected, paired iAEC2s (E690K, cE690; W308R, cW308 lines from Figure 1) and ABCA3:GFP+ WT (WT-AG) iAEC2s along with their paired CRISPR/Cas9 mutagenized iAEC2s (E690K-AG, W308R-AG from Figure 3). Biological replicates (n = 3) were each sorted on the indicated fluorochrome before RNA extraction. (B) Bar graph showing normalized enrichment scores (NES) of gene sets enriched in E690K patient iAEC2 (red bars) versus corrected cE690 iAEC2s (blue bars) following GSEA (FDR < 0.05). Gray bars, FDR > 0.05, ‡FDR = 0.26. ‡‡FDR = 0.46, ‡‡‡ FDR = 0.55. (C) Bar graph showing NES of gene sets enriched in W308R patient iAEC2s (red bars) versus corrected cW308 iAEC2s (blue bars) following GSEA (FDR < 0.05). (D) Bar graph showing NES of gene sets enriched in E690K-AG iAEC2s (red bars) versus WT-AG iAEC2s (blue bars) following GSEA (FDR < 0.05). (E) Bar graph showing NES of gene sets enriched in W308R-AG iAEC2s (red bars) versus WT-AG iAEC2s (blue bars) following GSEA (FDR < 0.05). Gray bars, FDR > 0.05. ‡FDR = 0.11. ‡‡FDR = 0.2, ‡‡‡FDR = 0.54.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts